Needham initiates coverage on Immix Biopharma with Buy rating

0 min read | Published on 22 Jul 2026, 06:30 PM |Updated on 22 Jul 2026, 06:30 PM

Reviewed by

Radhika SScanX News Team

Key Highlights

Needham analyst Gil Blum initiates coverage on Immix Biopharma with a Buy rating and a price target of $21, signaling confidence in the NASDAQ-listed biopharmaceutical company.

*this image is generated using AI for illustrative purposes only.

Needham analyst Gil Blum has initiated coverage on Immix Biopharma with a Buy rating and a price target of $21. The rating reflects a positive outlook on the company's performance and future prospects within the biopharmaceutical sector.

Immix Biopharma is listed on NASDAQ under the ticker symbol IMMX. The new coverage and price target provide investors with a benchmark for the stock's potential valuation.

Analyst	Firm	Rating	Price Target	Ticker
Gil Blum	Needham	Buy	$21	IMMX

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

What specific catalysts does Immix Biopharma have on the horizon that could drive the stock toward the $21 price target?

How might this new Buy rating influence investor sentiment and trading volume for IMMX in the short term?

What competitive advantages does Immix Biopharma have over other biopharmaceutical firms in its sector?

Law firms investigate Immix Biopharma after executive termination

1 min read | Published on 20 Jul 2026, 08:39 PM |Updated on 22 Jul 2026, 02:33 AM

Reviewed by

Naman SScanX News Team

Add as a preferred
source on Google

Key Highlights

Holzer & Holzer and The Portnoy Law Firm are investigating Immix Biopharma regarding potential federal securities law violations following the termination of an executive allegedly operating under a false identity. Immix disclosed the termination on July 17, 2026, stating it was unrelated to company activities, while the stock price subsequently fell by roughly 10.83%.

*this image is generated using AI for illustrative purposes only.

Holzer & Holzer, LLC and The Portnoy Law Firm are investigating Immix Biopharma, Inc. to determine if the company complied with federal securities laws. This follows Immix's disclosure that it terminated an executive serving under the alias "Richard Graydon," who was allegedly Ronald Fischer, a fugitive wanted in Rhode Island. Immix stated the officer was let go as of July 17, 2026, "for reasons unrelated to his activities at the Company," and management does not anticipate any material financial or operational impact due to his brief employment. Following the news, Immix's share price dropped by roughly 10.83%.

The Portnoy Law Firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors. Holzer & Holzer is also examining potential violations. Investors who purchased Immix stock and suffered losses are encouraged to contact these firms to discuss their legal rights.

Key Details

Detail	Information
Investigation Subject	Immix Biopharma, Inc. (NASDAQ: IMMX)
Allegation	Potential federal securities law violations
Executive Alias	Richard Graydon
Alleged Identity	Ronald Fischer
Termination Date	July 17, 2026
Share Price Impact	Dropped roughly 10.83%

Affected shareholders may reach out to Corey D. Holzer, Esq. or Joshua Karr, Esq. via email at cholzer@holzerlaw.com or jkarr@holzerlaw.com . Holzer & Holzer can be contacted by phone at (888) 508-6832. Alternatively, investors may contact attorney Lesley F. Portnoy at The Portnoy Law Firm by phone at 844-767-8529 or email at lesley@portnoylaw.com . The Portnoy Law Firm's founding partner has recovered over $5.5 billion for aggrieved investors.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

How will the ongoing investigations impact Immix Biopharma's ability to secure future funding or partnerships?

What measures will Immix implement to strengthen its vetting processes for executive hires?

Could the termination of the executive lead to further revelations about the company's internal controls?